Masami Komiya Selected Research

Intestinal Polyps

4/2020	Theracurmin inhibits intestinal polyp development in Apc-mutant mice by inhibiting inflammation-related factors.
1/2020	The Radical Scavenger NZ-419 Suppresses Intestinal Polyp Development in Apc-Mutant Mice.
1/2019	Novel screening system revealed that intracellular cholesterol trafficking can be a good target for colon cancer prevention.
5/2017	Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors.
4/2017	Impact of Acetazolamide, a Carbonic Anhydrase Inhibitor, on the Development of Intestinal Polyps in Min Mice.
4/2017	Preventive Effects of Heat-Killed Enterococcus faecalis Strain EC-12 on Mouse Intestinal Tumor Development.
11/2015	Suppressive effects of the NADPH oxidase inhibitor apocynin on intestinal tumorigenesis in obese KK-A(y) and Apc mutant Min mice.
3/2014	Sesamol suppresses cyclooxygenase-2 transcriptional activity in colon cancer cells and modifies intestinal polyp development in Apc (Min/+) mice.
12/2009	Overexpression of low-density lipoprotein receptor and lipid accumulation in intestinal polyps in Min mice.
4/2008	Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masami Komiya Research Topics

Disease

13	Carcinogenesis 11/2021 - 08/2008
13	Neoplasms (Cancer) 04/2020 - 10/2007
11	Intestinal Polyps 04/2020 - 10/2007
7	Colorectal Neoplasms (Colorectal Cancer) 03/2022 - 01/2012
7	Colonic Neoplasms (Colon Cancer) 11/2019 - 01/2012
6	Polyps 04/2020 - 12/2009
3	Inflammation (Inflammations) 04/2020 - 01/2012
3	Prostatic Neoplasms (Prostate Cancer) 01/2015 - 10/2012
2	Obesity 07/2021 - 01/2012
2	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2019 - 04/2008
2	Aberrant Crypt Foci 11/2015 - 01/2012
2	Adenocarcinoma 11/2012 - 08/2008
2	Hyperlipidemias (Hyperlipidemia) 10/2007 - 10/2007
1	Body Weight (Weight, Body) 07/2021
1	Chronic Renal Insufficiency 01/2020
1	Adenoma (Adenomas) 11/2012
1	Hyperplasia 08/2008
1	Pancreatic Neoplasms (Pancreatic Cancer) 08/2008

Drug/Important Bio-Agent (IBA)

11	Messenger RNA (mRNA)IBA 04/2020 - 10/2007
4	Interleukin-6 (Interleukin 6)IBA 04/2020 - 01/2012
4	Triglycerides (Triacylglycerol)IBA 01/2012 - 10/2007
3	Pharmaceutical PreparationsIBA 11/2021 - 05/2017
2	Insulin (Novolin)FDA Link 07/2021 - 01/2012
2	AntioxidantsIBA 01/2020 - 11/2019
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 11/2015
2	EnzymesIBA 11/2019 - 11/2015
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 05/2017 - 03/2014
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 11/2015 - 08/2008
2	AzoxymethaneIBA 11/2015 - 01/2012
2	Plasminogen Activator Inhibitor 1IBA 01/2014 - 04/2008
2	Indomethacin (Indometacin)FDA LinkGeneric 11/2012 - 10/2007
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2012 - 10/2007
2	AdipokinesIBA 01/2012 - 04/2008
2	LipidsIBA 12/2009 - 10/2007
1	colibactinIBA 03/2022
1	ArtesunateIBA 11/2021
1	Antimalarials (Antimalarial Agents)IBA 11/2021
1	Dietary CalciumIBA 07/2021
1	CalciumIBA 07/2021
1	2- amino- 1- methyl- 6- phenylimidazo(4,5- b)pyridineIBA 01/2021
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 04/2020
1	CurcuminIBA 04/2020
1	InterleukinsIBA 04/2020
1	CreatinineIBA 01/2020
1	Nuclear Antigens (Extractable Nuclear Antigens)IBA 01/2020
1	5-hydroxy-1-methylhydantoinIBA 01/2020
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2020
1	Hydroxyl RadicalIBA 01/2020
1	Transcription Factors (Transcription Factor)IBA 11/2019
1	LuciferasesIBA 11/2019
1	Annexin A5IBA 01/2019
1	fucoxanthinolIBA 01/2019
1	Propidium (Propidium Iodide)IBA 01/2019
1	Itraconazole (Sporanox)FDA LinkGeneric 01/2019
1	NF-kappa B (NF-kB)IBA 01/2019
1	CholesterolIBA 01/2019
1	OsteopontinIBA 05/2017
1	Erythromycin (Erycette)FDA LinkGeneric 05/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 05/2017
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 05/2017
1	Carbonic Anhydrase InhibitorsIBA 04/2017
1	Protons (Proton)IBA 04/2017
1	CytokinesIBA 04/2017
1	Carbon DioxideIBA 04/2017
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 04/2017
1	Bicarbonates (Hydrogen Carbonate)IBA 04/2017
1	Acetazolamide (Diamox)FDA LinkGeneric 04/2017
1	Cyclin D1IBA 04/2017
1	TCF Transcription FactorsIBA 04/2017
1	CateninsIBA 04/2017
1	NADPH Oxidases (NAD(P)H oxidase)IBA 11/2015
1	acetovanillone (apocynin)IBA 11/2015
1	Testosterone (Sustanon)FDA Link 04/2014
1	ProstaglandinsIBA 03/2014
1	GalactosidasesIBA 03/2014
1	Prostaglandin-E SynthasesIBA 03/2014
1	sesamolIBA 03/2014
1	Synthetic DrugsIBA 07/2013
1	Urethane (Ethyl Carbamate)IBA 11/2012
1	p38 Mitogen-Activated Protein KinasesIBA 10/2012
1	Telmisartan (Micardis)FDA Link 10/2012
1	Androgen Receptors (Androgen Receptor)IBA 10/2012
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 10/2012
1	candesartanIBA 10/2012
1	CaspasesIBA 10/2012
1	SK-1009IBA 01/2012
1	LigandsIBA 01/2012
1	Biological ProductsIBA 01/2012
1	Pioglitazone (Actos)FDA Link 01/2012
1	PPAR gammaIBA 01/2012
1	oil red OIBA 12/2009
1	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 12/2009
1	LDL Receptors (LDL Receptor)IBA 12/2009
1	Proteins (Proteins, Gene)FDA Link 08/2008
1	7- chloro- 3- imino- 5- methyl- 2- azabicyclo(4.1.0)heptaneIBA 08/2008
1	HeptanesIBA 08/2008

Therapy/Procedure

2	Castration 01/2015 - 10/2012
1	Immunotherapy 01/2015
1	Chemoprevention 07/2013
1	Intraperitoneal Injections 11/2012